

CUTANEOUS MEDICINE  
FOR THE PRACTITIONER  
A YORKE  
MEDICAL JOURNAL  
CAHNERS  
PUBLISHING COMPANY  
VOL. 48 NO. 5  
NOVEMBER 1991

# cutis®



\*\*\*\*\* 5-DIGIT 55455  
007 01943227  
MINNESOTA UNIVERSITY  
505 ESSEX STREET S E  
MINNEAPOLIS MN 55455

Pseudohorn Associated with Basal Cell Carcinoma

Philodendron-Induced Dermatitis

Aquagenic Pruritus

Complications of Ear Piercing



Dr. Reddy's Laboratories, Ltd., et al.  
v.  
Galderma Laboratories, Inc.  
IPR2015-\_\_\_\_\_

**DOCKET**  
**ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

## THERAPEUTICS FOR THE CLINICIAN

NEW REPORTS ON TREATMENT MODALITIES OF  
POSSIBLE INTEREST TO PATIENT-CARING PHYSICIANS

# Second-Generation Tetracyclines, A Dermatologic Overview: Clinical Uses and Pharmacology

Howard Maibach, MD, San Francisco, California

Tetracycline and its derivatives are frequently used in the treatment of acne, soft tissue bacterial infections, Lyme disease (borreliosis), chlamydial infections, and respiratory tract infections. Several pharmacologic and microbiological properties of these antibiotics make them particularly suitable for such uses. First-generation tetracyclines have long been in use; however, the second-generation tetracyclines minocycline, doxycycline hyclate, and doxycycline monohydrate have also become widely prescribed, and can offer advantages to the dermatologist over tetracycline.

This paper reviews the important pharmacologic and microbiological characteristics of these three commonly used second-generation tetracyclines, and their clinical applications in dermatology.

**M**inocycline and doxycycline, which are tetracycline structural analogs, have been used in human medicine for twenty-five years. Doxycycline and minocycline are differentiated from the original tetracyclines by structural differences in positions 5 and 6 (doxycycline) and by the substitution of a dimethylamino group in position 7 (minocycline). These substitutions cause few variations in the bacteriologic properties, but significantly enhance the physicochemical and pharmacokinetic properties, in particular, increasing their lipophilicity.

These compounds are obtained semisynthetically from oxytetracycline or methacycline and are significantly more lipophilic than tetracycline, which permits excellent tissue penetration. Higher lipophilicity results in a large volume of distribution, substantial binding to plasma proteins, and reabsorption in the renal tubules and gastrointestinal tract. This gives the drugs longer elimination half-lives. Excellent absorption after oral administration allows the use of low oral dosages and minimizes the side effects of tetracycline derivatives on the gastrointestinal tract.

Doxycycline is available in two forms: doxycycline hyclate, a salt form combining doxycycline (a weak base), hydrochloric acid (a strong acid), plus ethanol and water; and the more recently available doxycycline monohydrate, which is doxycycline free base with an associated water molecule.

### Pharmacologic Characteristics

**Antimicrobial Activity**—The tetracyclines are bacteriostatic through their ability to inhibit protein synthesis. This group of antibiotics is active against a broad range of gram-positive and gram-negative bacteria as well as *Mycoplasma*, *Ureaplasma*, and *Chlamydia*.

**Mechanism of Microbial Resistance**—Inherent in the use of all antibiotics is the appearance of resistant strains of micro-organisms. The degree of resistance is dependent upon several factors, including resistance of the host, concentration of the antibiotic, and even the location of the bacteria in the body. As with other antibiotics, resistant strains of micro-organisms have been observed with all tetracyclines.

Resistance to tetracycline is thought to occur as a result of either an altered ribosome (although tetracycline-resistant ribosomes have yet to be isolated) or the presence of a plasmid that decreases uptake of the antibiotic by the bacterium.<sup>1</sup> Resistance is usually conferred upon the bacteria in the form of R-plasmids.<sup>2,3</sup>

Resistance is defined within the parameters of the minimum inhibitory concentration of a drug required to inhibit bacterial growth. Minimum inhibitory concentration levels under 4 µg/ml are defined as "susceptible," from 4 to 16 µg/ml as "partially resistant," and levels over 16 µg/ml as "resistant."<sup>4</sup> Two types of resistance may be identified: a broad high-level resistance to all tetracyclines, and a moderate-level resistance in which the minimum inhibitory concentration of various micro-organisms increases in resistance from minocycline, through doxycycline, demethylchlortetracycline, and tetracycline to oxytetracycline.<sup>3,6</sup> Organisms resistant to tetracycline have been shown to be susceptible to doxycycline and minocycline.<sup>1,2</sup> In some instances of progressive resistance, the minimum inhibitory concentration for doxycycline is lower than for minocycline.<sup>7</sup>

REPRINT REQUESTS to the University of California Hospital, San Francisco, California 94143.

**Absorption/Distribution**—Doxycycline and minocycline are the best absorbed of the tetracyclines because of their high lipophilicity. This lipid solubility facilitates the transport of the drug across lipid-rich cell membranes and allows far better tissue penetration than all other tetracyclines. Distribution in body tissues is widespread and well documented.<sup>1,2,8</sup>

Absorption of orally administered doxycycline in a dose of 100 to 200 mg is greater than 80 percent, the mean values being closer to 95 percent. Doxycycline absorption is rapid, and is detectable in the blood fifteen to thirty minutes after administration.<sup>1,9-11</sup>

Minocycline is also 95 percent available following a 200 mg loading dose and maintenance dosages of 100 mg every twelve hours. Serum levels are detectable within one hour of administration.<sup>2,8,12,13</sup>

The major absorption site for both antibiotics is thought to be in the duodenum.<sup>1,2</sup> Several studies have shown that, at the same dosage, minocycline serum levels appear to peak somewhat earlier (approximately two hours) than those of doxycycline (approximately three hours), while the peak concentration of doxycycline is higher (approximately 7 µg/ml) than that of minocycline (approximately 5.5 µg/ml).<sup>14,15</sup>

No difference has been found in the absorption or bioavailability of the two derivatives of doxycycline, the monohydrate free base and the hydrochloride salt.<sup>9,16</sup>

**Fasting Not Required**—Doxycycline and minocycline may be administered with food or dairy products without causing a major reduction in absorption. Tetracycline absorption, however, is significantly influenced by food and dairy products. Welling et al studied the influence of various test meals and fluid volumes on the relative bioavailability of commercial formulations of tetracycline and doxycycline. Serum levels of tetracycline were uniformly reduced by 50 percent by all test meals, whereas serum levels of doxycycline were reduced by only 20 percent. The 50 percent reduction in tetracycline serum levels was found to have clinical significance.<sup>17</sup> Leyden investigated serum concentrations of tetracycline and minocycline when administered with water, milk, a meal, and 300 mg ferrous sulfate, and found absorption of tetracycline to be significantly decreased by administration with milk (-65 percent) and food (-46 percent). Minocycline absorption was affected less (27 percent and 13 percent reduction, respectively).<sup>18</sup>

Other studies have shown that the extent to which doxycycline and minocycline absorption is reduced when administered with food or dairy products is not clinically significant.<sup>1,2,9,19,14,17-24</sup> Pelletized minocycline and doxycycline are absorbed at a slower rate when taken with food than by a patient who has fasted.<sup>25,26</sup>

Because these antibiotics may be taken with meals, the incidence of gastric upset is reduced.<sup>1,2</sup> Patient compliance may be enhanced in two ways: a reduction in gastrointestinal distress, and the "memory jog" of taking their medication with, for example, their evening meal.

**Elimination**—Drug elimination may occur via two routes: metabolism or excretion. Efficient drug elimination is essential to avoid toxic accumulation in body tissues.

**Metabolism**—No doxycycline metabolites have been found in blood, urine, or feces.<sup>1,9</sup> Minocycline is partially degraded to three inactive metabolites in the liver.<sup>3,9</sup>

**Excretion**—Excretion of tetracycline takes place pri-

marily through glomerular filtration. Renal excretion of doxycycline and minocycline takes place in the kidney to a lesser extent than tetracycline, and both have a higher gastrointestinal excretion component than tetracycline.<sup>1,2,9,24</sup> Both doxycycline and minocycline concentrate in the bile, although this accounts for only a small portion of the administered dose, with primary gastrointestinal excretion resulting from secretion into the lumen.

Consistent with this elimination pattern, doxycycline serum levels are only minimally affected in patients with renal insufficiency and require no adjustment in dosage.<sup>1,24</sup> Minocycline elimination in patients with renal insufficiency also appears to be little changed due to the small amount normally excreted via that route, although several studies have presented conflicting data, some suggesting that a lowered dose may be warranted in patients with renal insufficiency.<sup>2,13,14,27-34</sup>

Doxycycline and minocycline have a longer half-life than the other tetracyclines, with reported half-lives for doxycycline varying between fifteen and twenty-five hours, while the half-life of minocycline is reported to be twelve to sixteen hours.<sup>2,9</sup>

## Physiological Variables

**Age and Gender**—Serum and tissue concentrations of doxycycline in elderly subjects are higher than those observed in young adults, and are thought to be due to decreased fecal elimination. The clinical significance of this accumulation is not clear, but adjustment of the dosage is probably unnecessary due to the drug's low toxicity. Adolescents appear to require a higher dosage than adults, although the specific mechanism involved is not known. No data are available concerning the use of minocycline in the elderly.<sup>9</sup>

There do not seem to be any gender-related modifications in the pharmacokinetic parameters of doxycycline. No data are available on minocycline.<sup>9</sup>

**Pregnancy and Lactation**—Doxycycline and minocycline are both excreted in breast milk.<sup>2,9</sup> Like other tetracyclines, doxycycline and minocycline are known to cause tooth discoloration (yellow-gray-brownish) during tooth development (last trimester of pregnancy, neonatal period, and early childhood). Use of tetracyclines should be avoided in pregnant and nursing women, and in infants and young children unless other therapeutic options are contraindicated.

**Drug Interactions**—Doxycycline and minocycline absorption is generally decreased by antacids, although they have less effect than on the other tetracyclines. Waiting three hours between administration of these drugs and an antacid should enable drug absorption to be virtually complete.<sup>9,14,35</sup> Iron also inhibits the absorption of doxycycline and minocycline, and should also only be administered after a three-hour interval.

## Adverse Reactions

Some of the adverse reactions associated with the use of second-generation tetracyclines are listed in Table I.

**Gastrointestinal**—Nausea, vomiting, and diarrhea are typical reactions that may occur with the tetracyclines, and appear to be dose related.<sup>1,2,24</sup>

**Central Nervous System**—Minocycline can produce

**TABLE I  
ADVERSE REACTIONS**

Drug	Potential Adverse Reactions				
	Esophageal Injury	Vertigo, Vestibular Symptoms	Photosensitivity	Photo-Onycholysis	Tissue Pigmentation
Minocycline	-	+	+/-	+/-	+
Doxycycline Hyclate	+	-	+	+	-
Doxycycline Monohydrate	-	-	+	+	-

dizziness, vertigo, or lightheadedness, which are apparently more common than those occurring after the administration of antihistamines, tranquilizers, sedatives, rifampin, penicillin, and the other tetracyclines.<sup>1,2,3,14,19,36-38</sup> Patients who experience this side effect should be cautioned not to drive or operate hazardous machinery while receiving therapy.<sup>26</sup> These vestibular effects are rarely seen in patients taking doxycycline.<sup>1,39</sup>

*Other*—Minocycline use, usually for prolonged periods, has been associated with hyperpigmentation of skin, thyroid, teeth, and bone. Pigmentation of the skin and mucous membranes occurs as a blue-gray discoloration at either the site of previous inflammation or in previously normal skin. A darker blue-gray or muddy brown discoloration may also occur in areas exposed to the sun. This effect is reported to fade with time. Thyroid discoloration is not known to cause any dysfunction.<sup>14,40-46</sup>

Of more concern, blood urea nitrogen concentrations during therapy with minocycline should be carefully monitored in patients with significant renal impairment due to the product's antianabolic activity.<sup>14</sup> Elevation in blood urea nitrogen levels in these patients appears to be dose related.<sup>26</sup> This problem has not been reported with doxycycline administration.<sup>1,47-57</sup>

*Phototoxicity*—Most currently prescribed tetracyclines are phototoxic to some extent. The mechanism of phototoxic reactions is not known, but may be associated with production of reactive oxygen radicals. Individual factors may also be of significance in the relationship of tetracycline derivatives and phototoxicity.

Most phototoxic reactions are manifest as an exaggerated sunburn or, more rarely, photo-onycholysis. The reported incidence with the use of doxycycline and minocycline is low (minocycline, less than 2 percent, doxycycline, less than 5 percent).<sup>2,14,39,58,59</sup> Doxycycline is widely used for the prevention of traveler's diarrhea in the tropics. The rate of reported photosensitivity is low.<sup>60</sup>

The relationship of tetracycline dosage, serum levels, and tissue levels with phototoxicity remains to be defined. Since this is a phototoxic and not an allergic reaction, there may be a dosage-dependent relationship. In the meantime, patients should be advised to minimize exposure to the sun while taking these antibiotics.

*Esophageal Irritation*—The acidic doxycycline hyclate salt (pH 2 to 3) is one of the most common causes of drug-induced esophageal ulceration. Most patients who experi-

enced esophageal ulcers reported that they had taken doxycycline with little or no water and then reclined.<sup>61-63</sup> The hyclate formulation is soluble at neutral pHs; hence, should the tablet or capsule become lodged in the esophagus due to insufficient liquid intake, reclining after taking the medication, or due to an esophageal stricture, it will dissolve rapidly and can cause esophageal irritation or ulceration.

Results of preclinical studies have shown that doxycycline monohydrate may significantly reduce the risk of esophageal injury due to its virtually neutral pH profile (pH 5 to 6). Furthermore, the monohydrate is not as soluble at esophageal pH, but is freely soluble in the gastric milieu, thereby dissolving more slowly than other salts in the esophagus but rapidly in the stomach. The substitution of doxycycline monohydrate for doxycycline hyclate may therefore reduce the risk of esophageal adverse reactions, particularly for patients who may have difficulty taking medication or following instructions.<sup>24,61-64</sup>

### Clinical Uses

Given the pharmacokinetics and in vitro spectrum of activity, the second-generation tetracyclines doxycycline and minocycline are ideally suited for treatment of two common dermatologic conditions: soft tissue infections and acne. In addition, doxycycline has been recommended by the Centers for Disease Control as the drug of choice for the treatment of genital chlamydial infections and for Lyme disease.

The simpler dosage regimen of these two compounds compared with tetracycline (twice daily rather than four times a day) and lowered dose (200 mg instead of 1000 mg) may enhance patient compliance. Furthermore, a once daily schedule at reduced doses for the treatment of acne has come under investigation and appears to show promise.

### Skin and Soft Tissue Infections

*Doxycyclines*—Doxycycline has been shown to be effective in treating a range of soft tissue infections, including infectious ulcers, cellulitis, gangrene, and a variety of abscesses, due to its broad spectrum of antibacterial activity and high lipid solubility.<sup>1</sup>

As part of a larger study, sixteen patients with acute traumatic infectious ulcers of the lower extremities were treated with oral doxycycline; fifteen of the patients' conditions (94 percent) responded to treatment.<sup>1,65</sup> In another

study of soft tissue infections, primarily cellulitis and abscess, the clinical response was good in 81 percent of the patients, satisfactory in 16 percent, and poor in 4 percent. *Staphylococcus aureus*, beta-hemolytic *Streptococcus*, and *Escherichia coli* were the most frequently isolated pathogens and showed an excellent bacteriologic response. The small number of less favorable responses resulted from cases in which *Proteus*, *Klebsiella*, or *Pseudomonas* sp. were isolated.<sup>1,66</sup>

A further study evaluated combined intravenous and oral doxycycline in the treatment of soft tissue infection, primarily perirectal abscess, cellulitis, gangrene, and pedal or other superficial abscesses. A good clinical response was seen in 78 percent of the patients, 22 percent showed satisfactory results, and no clinical failures were noted.<sup>1,67</sup>

**Minocycline**—Minocycline has demonstrated efficacy in soft tissue infections caused by *Staphylococcus aureus*, although tetracyclines are not the drug of choice in patients with any type of staphylococcal infection.<sup>14</sup>

Minocycline has also been successfully used in treating infections due to *Mycobacterium marinum*, although optimal dosages have not been established.<sup>14,68-72</sup> Pyoderma gangrenosum has been successfully treated with a higher dosage minocycline (300 mg/day) over an extended period of time.<sup>14,73,74</sup> Minocycline has also been used to treat mycetoma and *Serratia granuloma*.<sup>14,75,76</sup>

**Acne**—The use of antibiotics in the treatment of acne vulgaris is based on research on the interaction of hormones, sebaceous glands, and bacteria. Free fatty acids are generally considered the primary source of irritation, and are produced both in the pilosebaceous canals and on the skin surface by the hydrolysis of triglycerides in sebum. The hydrolyzing agents are lipases of aerobic coagulase-negative *Staphylococcus epidermidis* and anaerobic *Propionibacterium acnes*, both of which are flora of normal skin. Successful treatment of acne with antibiotics may prevent bacterial lipases from forming the irritant free fatty acids or may eliminate the causative bacteria.<sup>77</sup>

Tetracyclines have been used successfully for years in the treatment of acne.<sup>77-79</sup> They are believed to lower the production of free fatty acids either indirectly by interfering with nucleic acid metabolism and protein synthesis, thus decreasing the bacterial population and attendant lipases, or directly by binding lipases so that they cannot hydrolyze triglycerides. In fact, both processes may be involved.<sup>77</sup>

The doxycyclines and minocycline have an advantage over tetracycline because of their higher degree of lipophilicity/absorption. A lower dosage regimen than with tetracycline is therefore possible, providing for greater patient compliance. The ability of doxycyclines and minocycline to be administered with food further enhances patient compliance, as has been discussed already. The efficacy of doxycycline and minocycline in the treatment of acne will be summarized.

**Doxycycline vs. Placebo**—In an early double-blind crossover study of sixty-two patients with acne vulgaris that compared doxycycline at 50 mg twice daily to placebo, Plewig et al.<sup>80</sup> showed a highly significant improvement in the twenty-eight patients initially randomized to receive doxycycline ( $p$  is less than 0.001). During the four-week rest period, the twenty-eight patients initially treated with doxycycline showed significant worsening of their symptoms ( $p$  is less than 0.05). In phase 2, the thirty-four subjects initially treated with placebo showed significant improvement ( $p$  is less than 0.05) in reduc-

tion of inflammatory lesions when crossed over to receive doxycycline. Patients receiving placebo in either phase 1 or 2 showed no significant reduction in number of lesions.

Another double-blind twelve-week study compared two dosages of doxycycline, 50 mg daily and 100 mg daily, to placebo.<sup>81</sup> After four weeks of treatment, 68 percent of patients treated with 100 mg doxycycline were judged to be "cured" compared with 27 percent of placebo-treated patients. In the 50 mg doxycycline-treated group, 72 percent were judged "cured" after six weeks of therapy compared to 27 percent of those receiving placebo. At week twelve, the percentage of "cured" patients was 90 percent compared with 89 percent for the 100 mg and 50 mg doxycycline-treated groups, respectively.

**Minocycline vs. Placebo**—A double-blind crossover study was conducted in fifty patients with acne vulgaris. In the first phase, minocycline or placebo was administered to patients: 200 mg daily for seven days, followed by 100 mg daily for five weeks. The two groups' treatments were switched for the last five weeks of therapy. There was a significant decrease ( $p$  is less than 0.05) in baseline acne lesion counts in the group taking minocycline, while the decrease in placebo-treated patients was not significant.<sup>14,82</sup>

**Minocycline vs. Tetracycline**—Minocycline has been compared in a number of studies to tetracycline in the treatment of acne and has been equally effective or superior in some respects.<sup>14,83-86</sup> A few are summarized here.

In one double-blind six-month study, 104 patients received either minocycline 50 mg/twice daily or tetracycline 250 mg/twice daily.<sup>14,84</sup> Although there were no statistical differences between the groups in the number of patients who reached and maintained grade I (noninflammatory) status, a higher percentage of the minocycline-treated patients (92 percent) reached that status more quickly (sixty-three days) than did tetracycline-treated patients (75 percent at seventy-six days). Seventeen patients reported side effects; these occurred equally in the two treatment groups.

In another study, fifty patients were treated with either 50 mg minocycline twice daily or 250 mg tetracycline twice daily for eighteen weeks. Eighty-six percent of the minocycline-treated patients and 80 percent of the tetracycline-treated patients exhibited a satisfactory clinical response. Two patients from each group experienced drug-related side effects.<sup>14,83</sup>

**Doxycycline vs. Minocycline**—In an early study,<sup>87</sup> sixteen patients with acne were treated with either minocycline or doxycycline at 100 mg/day for twelve days. Both drugs appeared to have similar efficacy; no patients dropped out of the study due to adverse side effects.

In 1988, Harrison completed an observer-blinded twelve-week study comparing doxycycline 50 mg/once daily to minocycline 50 mg/twice daily.<sup>88</sup> Treatment efficacy was considered good or excellent in 73 percent of the doxycycline-treated group compared with 84 percent in the minocycline-treated group; the difference was not statistically significant. Side effects were minimal in both groups; only one patient in the doxycycline-treated group and two patients in the minocycline-treated group experienced treatment-related side effects.

More recently, doxycycline and minocycline were compared in an open study over a twelve-week period, with 100 patients receiving either doxycycline 50 mg once daily or

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.